BMC nephrology · 2025
Iptacopan in C5 blockade refractory atypical hemolytic uremic syndrome with associated Castleman's disease: case report.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nguyen Matthew D, Ciurea Stefan, Desai Sheetal, Kalebasty Arash Rezazadeh, Tran Minh-Ha, Gee Caroline, Tadros Mina, Nguyen Vu Q, Patel Samir, Selamet Umut, Hanna Ramy
Аннотация
BACKGROUND: Atypical Hemolytic Uremic Syndrome (aHUS) is a life-threatening disease related to mutations in the complement system. We report the first known case of the use of factor B inhibition in a 21-year-old male with complement-mediated thrombotic microangiopathy (CMTMA), later found to have Castleman's disease as a mimicker of aHUS.
CASE PRESENTATION: Initially, the patient partially responded to eculizumab and then fully to ravulizumab. However, two years later, he experienced a flare that did not improve with ravulizumab redosing. An application for the compassionate use of Iptacopan was approved by the United States Food and Drug Administration, based on its success in C5 blockade Paroxysmal Nocturnal Hemoglobinuria. The patient's blood counts recovered, his microangiopathic hemolytic anemia ceased, and his acute kidney injury resolved allowing cessation of renal replacement therapy. Human Anti-murine anti-drug antibodies were suspected as the cause of C5 blockade failure but were unconfirmed. Ten months later, the patient's aHUS relapsed and he was concurrently diagnosed with Castleman's syndrome, a mimicker of aHUS, prompting the initiation of dual combination therapy of C5 blockade inhibitor and Factor B inhibitor and siltuximab.
CONCLUSIONS: This case marks the first use of Iptacopan for aHUS/CMTMA and the first use of dual combination therapy of eculizumab and Factor B Inhibition for patients with aHUS/CMTMA and Castleman's disease in the United States at the University of California Irvine by our thrombotic microangiopathy assessment team.
CLINICAL TRIAL: N/A, this study is not a clinical trial.
CASE PRESENTATION: Initially, the patient partially responded to eculizumab and then fully to ravulizumab. However, two years later, he experienced a flare that did not improve with ravulizumab redosing. An application for the compassionate use of Iptacopan was approved by the United States Food and Drug Administration, based on its success in C5 blockade Paroxysmal Nocturnal Hemoglobinuria. The patient's blood counts recovered, his microangiopathic hemolytic anemia ceased, and his acute kidney injury resolved allowing cessation of renal replacement therapy. Human Anti-murine anti-drug antibodies were suspected as the cause of C5 blockade failure but were unconfirmed. Ten months later, the patient's aHUS relapsed and he was concurrently diagnosed with Castleman's syndrome, a mimicker of aHUS, prompting the initiation of dual combination therapy of C5 blockade inhibitor and Factor B inhibitor and siltuximab.
CONCLUSIONS: This case marks the first use of Iptacopan for aHUS/CMTMA and the first use of dual combination therapy of eculizumab and Factor B Inhibition for patients with aHUS/CMTMA and Castleman's disease in the United States at the University of California Irvine by our thrombotic microangiopathy assessment team.
CLINICAL TRIAL: N/A, this study is not a clinical trial.